FDA Announces Final Decision on Withdrawal of PEPAXTO (melphalan flufenamide) Approval

Summary

The FDA has made a final decision to withdraw approval of PEPAXTO, a cancer treatment, following a public comment period and review by an advisory committee, after Oncopeptides AB appealed the proposed withdrawal.